Hossein Ardehali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hossein Ardehali has a total of 250 co-authors. Here are the top co-authors by number of shared publications:
- Hsiang-Chun Chang
Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine
20 shared publications Rongxue Wu
Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine
14 shared publicationsMarina Bayeva
Feinberg Cardiovascular Research Institute, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611
13 shared publicationsHsiang-Chun Chang
Feinberg Cardiovascular and Renal Research Institute, Northwestern University
12 shared publications- Jason Solomon Shapiro
Feinberg Cardiovascular and Renal Research Institute, Northwestern University
12 shared publications Jason S. Shapiro
Feinberg Cardiovascular and Renal Research Institute and Department of Medicine (Cardiology), Northwestern University, Chicago, IL 60611, USA
10 shared publications
Latest Publications
- 28 August 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (6)
Microglia Drive Hypothalamic Inflammation in HFpEF Through Extracellular Vesicles Released From the Heart
- 28 August 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (6)
Microglia Drive Hypothalamic Inflammation in HFpEF Through Extracellular Vesicles Released From the Heart
- Open Access
- 30 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (18)
Ferroptosis as a target mechanism in heart and kidney disease
Ferroptosis is a distinct form of regulated cell death driven by lipid peroxidation and redox imbalance. Since its formal recognition in 2012, ferroptosis has emerged as a central pathway linking metabolic stress and oxidative injury to both physiologic and pathologic processes. Its functions extend from tissue sculpting during embryogenesis and tumor suppression to pathologic contributions in neurodegeneration, cardiovascular disease, liver and kidney injury, cancer, and inflammatory disorders. Despite these advances in our understanding of ferroptosis, critical questions remain regarding its precise regulation, context-specific consequences, and interactions with other cell death pathways. Continued progress in identifying biomarkers, defining context-specific roles, and developing selective modulators will be essential to translate ferroptosis biology into clinical therapies with broad impact. Here, we describe the current state of our understanding of the role of ferroptosis in physiology and its potential as a target mechanism in heart and kidney disease.
- 30 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (18)
Open AccessFerroptosis as a target mechanism in heart and kidney disease
Ferroptosis is a distinct form of regulated cell death driven by lipid peroxidation and redox imbalance. Since its formal recognition in 2012, ferroptosis has emerged as a central pathway linking metabolic stress and oxidative injury to both physiologic and pathologic processes. Its functions extend from tissue sculpting during embryogenesis and tumor suppression to pathologic contributions in neurodegeneration, cardiovascular disease, liver and kidney injury, cancer, and inflammatory disorders. Despite these advances in our understanding of ferroptosis, critical questions remain regarding its precise regulation, context-specific consequences, and interactions with other cell death pathways. Continued progress in identifying biomarkers, defining context-specific roles, and developing selective modulators will be essential to translate ferroptosis biology into clinical therapies with broad impact. Here, we describe the current state of our understanding of the role of ferroptosis in physiology and its potential as a target mechanism in heart and kidney disease.
- Open Access
- 2 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (14)
SEC16B identified as a regulator of VLDL secretion and lipid accumulation in the liver
The liver plays a major role in regulating the metabolic fate of lipids and facilitates lipid secretion to peripheral organs in the form of VLDLs or lipid storage in lipid droplets (LDs). Hepatic regulation of excess lipids profoundly influences the development of atherosclerosis; thus, uncovering the regulatory mechanisms underlying lipid storage and secretion pathways may reveal additional therapeutic targets. In this issue of the JCI , Lu et al. identified a pathway involving SEC16B, showing that this protein functions as a lipid-responsive regulator and mediates VLDL secretion and LD formation to maintain lipid homeostasis. They also demonstrated that a reduction in SEC16B reduced serum lipid levels and atherosclerotic plaque area in Ldlr –/– mice. These results indicate that SEC16B connects VLDL and LD metabolism, positioning SEC16B as a potential therapeutic avenue for atherosclerosis.
- 2 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (14)
Open AccessSEC16B identified as a regulator of VLDL secretion and lipid accumulation in the liver
The liver plays a major role in regulating the metabolic fate of lipids and facilitates lipid secretion to peripheral organs in the form of VLDLs or lipid storage in lipid droplets (LDs). Hepatic regulation of excess lipids profoundly influences the development of atherosclerosis; thus, uncovering the regulatory mechanisms underlying lipid storage and secretion pathways may reveal additional therapeutic targets. In this issue of the JCI , Lu et al. identified a pathway involving SEC16B, showing that this protein functions as a lipid-responsive regulator and mediates VLDL secretion and LD formation to maintain lipid homeostasis. They also demonstrated that a reduction in SEC16B reduced serum lipid levels and atherosclerotic plaque area in Ldlr –/– mice. These results indicate that SEC16B connects VLDL and LD metabolism, positioning SEC16B as a potential therapeutic avenue for atherosclerosis.
- Open Access
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (2)
Caught in the crossfire: cardiac complications of cancer therapy
Advances in cancer therapy have greatly extended patient survival but have also introduced a growing burden of cardiovascular toxicity that threatens long-term outcomes. These toxicities encompass a broad and often unpredictable range of clinical presentations, complicating oncologic care. Understanding how chemotherapy, targeted agents, and immune modulators impair cardiovascular function is essential for early detection, prevention, and management. Emerging insights into the cellular and molecular mechanisms, ranging from immune activation to transcriptional reprogramming and disrupted intercellular communication, underscore the complexity of cancer therapy–induced cardiac injury. Unraveling these mechanisms will be key to developing personalized, mechanism-based strategies that preserve cardiac function without compromising anticancer efficacy. As survivorship continues to improve, mitigating cardiotoxicity remains a critical priority for preserving both the quality and duration of life of patients.
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (2)
Open AccessCaught in the crossfire: cardiac complications of cancer therapy
Advances in cancer therapy have greatly extended patient survival but have also introduced a growing burden of cardiovascular toxicity that threatens long-term outcomes. These toxicities encompass a broad and often unpredictable range of clinical presentations, complicating oncologic care. Understanding how chemotherapy, targeted agents, and immune modulators impair cardiovascular function is essential for early detection, prevention, and management. Emerging insights into the cellular and molecular mechanisms, ranging from immune activation to transcriptional reprogramming and disrupted intercellular communication, underscore the complexity of cancer therapy–induced cardiac injury. Unraveling these mechanisms will be key to developing personalized, mechanism-based strategies that preserve cardiac function without compromising anticancer efficacy. As survivorship continues to improve, mitigating cardiotoxicity remains a critical priority for preserving both the quality and duration of life of patients.
- 3 July 2025
- Published by Springer Nature
- Vol. 1480, 217-236
Iron Metabolism in Cardiovascular Disease
Iron is pivotal in energy-demanding cells such as cardiomyocytes, supporting its critical functions such as electron transfer and energy production. Systemically, iron is mainly absorbed through the gut or through red blood cell turnover by macrophages. This involves the complex interplay of transporters and regulatory proteins such as transferrin, hepcidin, and ferroportin. Intracellularly, iron is regulated by iron regulatory proteins and mRNA-binding proteins such as tristetraprolin, maintaining iron balance within cardiomyocytes. However, iron dysregulation can manifest as iron deficiency or iron overload, each leading to distinct cardiovascular diseases, particularly heart failure, anthracycline-induced cardiotoxicity, hemochromatosis, and Friedreich’s ataxia. Recent clinical trials have investigated the efficacy of intravenous iron supplementation in patients with heart failure and certain criteria for iron deficiency. These trials have examined the efficacy of these therapies in improving heart failure symptoms, hospitalizations, and mortality. Moreover, emerging biomarkers like soluble transferrin-receptors are showing promise in refining the diagnosis of iron deficiency anemia. Here, we discuss the role of iron dysregulation in cardiovascular diseases, therapeutic strategies in heart failure, and future perspectives.
- 3 July 2025
- Published by Springer Nature
- Vol. 1480, 217-236
Iron Metabolism in Cardiovascular Disease
Iron is pivotal in energy-demanding cells such as cardiomyocytes, supporting its critical functions such as electron transfer and energy production. Systemically, iron is mainly absorbed through the gut or through red blood cell turnover by macrophages. This involves the complex interplay of transporters and regulatory proteins such as transferrin, hepcidin, and ferroportin. Intracellularly, iron is regulated by iron regulatory proteins and mRNA-binding proteins such as tristetraprolin, maintaining iron balance within cardiomyocytes. However, iron dysregulation can manifest as iron deficiency or iron overload, each leading to distinct cardiovascular diseases, particularly heart failure, anthracycline-induced cardiotoxicity, hemochromatosis, and Friedreich’s ataxia. Recent clinical trials have investigated the efficacy of intravenous iron supplementation in patients with heart failure and certain criteria for iron deficiency. These trials have examined the efficacy of these therapies in improving heart failure symptoms, hospitalizations, and mortality. Moreover, emerging biomarkers like soluble transferrin-receptors are showing promise in refining the diagnosis of iron deficiency anemia. Here, we discuss the role of iron dysregulation in cardiovascular diseases, therapeutic strategies in heart failure, and future perspectives.
- 22 April 2025
- Published by Elsevier in Cell Metabolism
- Vol. 37 (7) , 1584-1600.e10
Protein O-GlcNAcylation and hexokinase mitochondrial dissociation drive heart failure with preserved ejection fraction
- 22 April 2025
- Published by Elsevier in Cell Metabolism
- Vol. 37 (7) , 1584-1600.e10
Protein O-GlcNAcylation and hexokinase mitochondrial dissociation drive heart failure with preserved ejection fraction
- Open Access
- 27 September 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Human induced pluripotent stem cell-derived cardiomyocytes to study inflammation-induced aberrant calcium transient
Heart failure with preserved ejection fraction (HFpEF) is commonly found in persons living with HIV (PLWH) even when antiretroviral therapy suppresses HIV viremia. However, studying this condition has been challenging because an appropriate animal model is not available. In this article, we studied calcium transient in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in culture to simulate the cardiomyocyte relaxation defect noted in PLWH and HFpEF and assess whether various drugs have an effect. We show that treatment of hiPSC-CMs with inflammatory cytokines (such as interferon-γ or TNF-α) impairs their Ca2+ uptake into sarcoplasmic reticulum and that SGLT2 inhibitors, clinically proven as effective for HFpEF, reverse this effect. Additionally, treatment with mitochondrial antioxidants (like mito-Tempo) and certain antiretrovirals resulted in the reversal of the effects of these cytokines on calcium transient. Finally, incubation of hiPSC-CMs with serum from HIV patients with and without diastolic dysfunction did not alter their Ca2+-decay time, indicating that the exposure to the serum of these patients is not sufficient to induce the decrease in Ca2+ uptake in vitro. Together, our results indicate that hiPSC-CMs can be used as a model to study molecular mechanisms of inflammation-mediated abnormal cardiomyocyte relaxation and screen for potential new interventions.
- 27 September 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessHuman induced pluripotent stem cell-derived cardiomyocytes to study inflammation-induced aberrant calcium transient
Heart failure with preserved ejection fraction (HFpEF) is commonly found in persons living with HIV (PLWH) even when antiretroviral therapy suppresses HIV viremia. However, studying this condition has been challenging because an appropriate animal model is not available. In this article, we studied calcium transient in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in culture to simulate the cardiomyocyte relaxation defect noted in PLWH and HFpEF and assess whether various drugs have an effect. We show that treatment of hiPSC-CMs with inflammatory cytokines (such as interferon-γ or TNF-α) impairs their Ca2+ uptake into sarcoplasmic reticulum and that SGLT2 inhibitors, clinically proven as effective for HFpEF, reverse this effect. Additionally, treatment with mitochondrial antioxidants (like mito-Tempo) and certain antiretrovirals resulted in the reversal of the effects of these cytokines on calcium transient. Finally, incubation of hiPSC-CMs with serum from HIV patients with and without diastolic dysfunction did not alter their Ca2+-decay time, indicating that the exposure to the serum of these patients is not sufficient to induce the decrease in Ca2+ uptake in vitro. Together, our results indicate that hiPSC-CMs can be used as a model to study molecular mechanisms of inflammation-mediated abnormal cardiomyocyte relaxation and screen for potential new interventions.
- Open Access
- 19 September 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (19)
Joel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen awarded Lasker prize for pioneering work on GLP-1
Bjerre Knudsen (Novo Nordisk) for their pioneering work on glucagon-like peptide 1 (GLP-1) receptor agonists and their applications
- 19 September 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (19)
Open AccessJoel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen awarded Lasker prize for pioneering work on GLP-1
Bjerre Knudsen (Novo Nordisk) for their pioneering work on glucagon-like peptide 1 (GLP-1) receptor agonists and their applications
- Open Access
- 4 September 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Human induced pluripotent stem cell-derived cardiomyocytes to study inflammation-induced aberrant calcium transient
Heart failure with preserved ejection fraction (HFpEF) is commonly found in persons living with HIV (PLWH) even when antiretroviral therapy (ART) suppresses HIV viremia. However, studying this condition has been challenging because an appropriate animal model is not available. In this paper, we studied calcium transient in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in culture to simulate the cardiomyocyte relaxation defect noted in of PLWH and HFpEF and to assess whether various drugs have an effect. We show that treatment of hiPSC-CMs with inflammatory cytokines (such as interferon-γ or TNF-α) impair their Ca2+ uptake into sarcoplasmic reticulum and that SGLT2 inhibitors, clinically proven as effective for HFpEF, reverse this effect. Additionally, treatment with mitochondrial antioxidants (like mito-Tempo) and certain antiretrovirals resulted in the reversal of the effects of these cytokines on calcium transient. Finally, incubation of hiPSC-CMs with serum from HIV patients with and without diastolic dysfunction did not alter their Ca2+-decay time, indicating that the exposure to the serum of these patients is not sufficient to induce the decrease in Ca2+ uptake in vitro. Together, our results indicate that hiPSC-CMs can be used as a model to study molecular mechanisms of inflammation-mediated abnormal cardiomyocyte relaxation and screen for potential new interventions.
- 4 September 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Open AccessHuman induced pluripotent stem cell-derived cardiomyocytes to study inflammation-induced aberrant calcium transient
Heart failure with preserved ejection fraction (HFpEF) is commonly found in persons living with HIV (PLWH) even when antiretroviral therapy (ART) suppresses HIV viremia. However, studying this condition has been challenging because an appropriate animal model is not available. In this paper, we studied calcium transient in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in culture to simulate the cardiomyocyte relaxation defect noted in of PLWH and HFpEF and to assess whether various drugs have an effect. We show that treatment of hiPSC-CMs with inflammatory cytokines (such as interferon-γ or TNF-α) impair their Ca2+ uptake into sarcoplasmic reticulum and that SGLT2 inhibitors, clinically proven as effective for HFpEF, reverse this effect. Additionally, treatment with mitochondrial antioxidants (like mito-Tempo) and certain antiretrovirals resulted in the reversal of the effects of these cytokines on calcium transient. Finally, incubation of hiPSC-CMs with serum from HIV patients with and without diastolic dysfunction did not alter their Ca2+-decay time, indicating that the exposure to the serum of these patients is not sufficient to induce the decrease in Ca2+ uptake in vitro. Together, our results indicate that hiPSC-CMs can be used as a model to study molecular mechanisms of inflammation-mediated abnormal cardiomyocyte relaxation and screen for potential new interventions.